Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

Share Price is delayed by 15 minutes
Get Live Data
55.50    -0.50 (-0.89%)
Bid:
55.00
Ask:
56.00
Spread: 1.00 (1.818%)
Market Cap: £8.45m
TRT Live PriceLast checked at - London Stock Exchange

Intraday Transense Share Chart

Share Repurchase Programme

27 Sep 2022 07:01

RNS Number : 7146A
Transense Technologies PLC
27 September 2022
 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

27 September 2022

 

Transense Technologies plc

("Transense", or "the Company")

 

Share Repurchase Programme

 

Transense Technologies plc (AIM: TRT), the developer of specialist sensor systems, is pleased to announce that it will commence a programme to conduct market purchases of ordinary shares of 10 pence each in the Company ("Ordinary Shares") up to a maximum aggregate purchase price of £650,000 (the "Programme").

 

The Company has entered into an arrangement with Shard Capital Stockbrokers ("Shard") in relation to the Programme where Shard will make the trading decisions concerning the timing of the market purchases of Ordinary Shares independently of and uninfluenced by the Company, with such trading decisions being in accordance with the terms of the Programme. Purchases may continue during any periods during the term of the Programme when the Company itself would be prohibited from dealing by the UK version of the Market Abuse Regulation 596/2014/EU (which is part of UK law by virtue of the European Union (Withdrawal) Act 2018) ("UK MAR"). The Company reserves the right to terminate the Programme if at any time it deems this to be appropriate and would make an announcement in advance of so doing.

 

The Company confirms that it currently has no unpublished inside information.

 

The Programme will commence today, 27 September 2022, and will continue until 30 November 2023 unless terminated earlier.

 

The Programme will be conducted by the Company in accordance with and under the terms of the general authority granted by the Company's shareholders at the Company's Annual General Meeting on 23 November 2021 to purchase up to 1,643,774 Ordinary Shares. This authority will expire at the earlier of the end of the next Annual General Meeting of the Company or 23 February 2023. Purchases under the Programme prior to the Annual General Meeting of the Company to be held on 1 December 2022 will be restricted to an aggregate of £150,000, and the balance of the Programme will continue after the Annual General Meeting subject to renewal of the appropriate authority by the shareholders.

 

Any market purchases will be conducted in compliance with the following restrictions regarding price conditions:

· the minimum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be its nominal value of 10 pence

· the maximum price (exclusive of any expenses) at which any Ordinary Share may be purchased shall be the higher of: (i) an amount equal to 5 per cent, above the average of the middle market quotations of an Ordinary Share as derived from the London Stock Exchange Daily Official List for the five business days immediately preceding the date of such purchase, and (ii) the higher of the price of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out.

 

Due to the limited liquidity in the Ordinary Shares, any market purchase of Ordinary Shares pursuant to the Programme on any trading day could represent a significant proportion of the daily trading volume in the Ordinary Shares on AIM and could exceed 25 per cent. of the average daily trading volume. This means that the Company will not benefit from the exemption contained in Article 5(1) of UK MAR.

 

The objective of the Programme is to offset the dilutive impact of share awards to directors and employees.

 

Ordinary Shares acquired as a result of the Programme will be held by the Company in treasury and in accordance with the Companies Act 2006, will not have any voting rights. It is anticipated that any Ordinary Shares held in treasury but surplus to unexercised option requirements from time to time will be cancelled.

 

For further information please visit www.transense.com or contact:

 

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Melvyn Segal (CFO)

Via Walbrook PR

Allenby Capital (Nominated Adviser and Broker)

Jeremy Porter / George Payne (Corporate Finance)

Tony Quirke (Sales & Corporate Broking)

Tel: +44 (0)20 3328 5656

Walbrook PR

Tom Cooper / Nick Rome

Tel: +44 (0)20 7933 8780

Transense@walbrookpr.com

 

Notes to Editors:

Transense is a developer of specialist wireless sensor systems used to enable real-time data gathering and monitoring. Products include the patent protected Surface Acoustic Wave (SAW) sensor technology, used to improve equipment power, performance, reliability and efficiency; iTrack, Transense 's Tyre Pressure Monitoring System, licensed to Bridgestone Corporation, the world's largest tyre producer, under a ten-year deal in June 2020; and a range of intelligent tyre monitoring equipment under the Translogik brand. Target sectors include aerospace, electric motors & drives, industrial machinery and performance automotive. 

The Company's strategy is to maximise shareholder value through the delivery of sustained revenue growth from all three principal technologies - SAW, iTrack and Translogik probes - through leveraging excellence in innovation, know-how in commercialising technologies, industry partnerships and exposure to global growth markets.

Transense is headquartered in Oxfordshire, UK, and was admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT), in 1999.  www.transense.com.

For further information please contact transense@walbrookpr.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFEAARIRFIF
Date   Source Headline
1st Apr 20193:02 pmRNSResult of General Meeting
22nd Mar 201910:30 amRNSHolding(s) in Company
20th Mar 201910:02 amRNSHolding(s) in Company
15th Mar 20199:33 amRNSNotice of GM and Posting of Circular
14th Mar 20193:30 pmRNSEIS Advance Assurance and Total Voting Rights
13th Mar 20193:35 pmRNSInterim Results
13th Mar 20193:35 pmRNSPlacing & General Meeting
22nd Feb 20198:36 amRNSHolding(s) in Company
20th Feb 20198:30 amRNSiTrack Contract Win
18th Feb 20197:00 amRNSSignificant iTrack Order
4th Feb 20197:00 amRNSGE Aviation Contract Win
21st Dec 20181:22 pmRNSResult of AGM
21st Dec 20187:00 amRNSAGM Statement
21st Nov 20187:00 amRNSNotice of AGM
12th Nov 20187:00 amRNSTranslogik iTrack Contract Win in new Territory
9th Oct 20187:00 amRNSFinal Results
26th Sep 20187:00 amRNSNotice of Results
23rd Aug 20182:44 pmRNSHolding(s) in Company
1st Aug 20187:00 amRNSTrading Update
25th Jun 20188:29 amRNSHolding(s) in Company
21st Jun 20182:33 pmRNSResult of General Meeting
31st May 20187:00 amRNSPlacing and Notice of General Meeting
8th May 20187:00 amRNSNew Translogik iTrack Contract Win
2nd Mar 201812:26 pmRNSStatement re joint broker
7th Feb 20187:00 amRNSInterim Results
5th Feb 20189:56 amRNSHolding(s) in Company
21st Dec 20171:09 pmRNSResult of AGM
21st Dec 20177:00 amRNSAGM Statement
18th Dec 201711:18 amRNSIssue of Equity
27th Nov 20179:29 amRNSContract Win
14th Nov 20177:00 amRNSNotice of AGM
26th Sep 20177:00 amRNSFinal Results
5th Sep 20177:00 amRNSNotice of Results
5th Sep 20177:00 amRNSInvestor Event
7th Aug 20177:00 amRNSNew iTrack Contract Win with BHP in Australia
31st Jul 20177:00 amRNSTrading Update
27th Jun 20177:00 amRNSAward of options
26th Jun 20177:00 amRNSGlencore - Further Contract Win
6th Jun 20177:00 amRNSDirector/PDMR Shareholding
5th Jun 20177:00 amRNSGlencore - Further Contract Win
4th Apr 20175:20 pmRNSHolding(s) in Company
29th Mar 20177:01 amRNSInterim results
29th Mar 20177:00 amRNSFurther Payment from General Electric
1st Mar 20177:00 amRNSInvestor Event
28th Feb 20171:54 pmRNSNotice of Results
27th Jan 20177:00 amRNSIssue of Equity
22nd Dec 20168:19 amRNSCapital Reduction
23rd Nov 20163:45 pmRNSResult of AGM & Share Consolidation
23rd Nov 20167:00 amRNSAGM Statement
21st Sep 20167:00 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.